Anticancer research · 2026
Synergistic Anticancer Effects of the PLK1 Inhibitor BI-2536 and β-Glucan in Colon and Gastric Cancer Cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takci Rabia Gökçe, Saraç Bülent, Hacisüleyman Levent, Şahinbaş Burcu, Joha Ziad
Аннотация
BACKGROUND/AIM: Colon and gastric cancers are among the most prevalent gastrointestinal malignancies, often exhibiting poor prognosis due to resistance and recurrence. Polo-like kinase 1 (PLK1), a key regulator of mitosis, is frequently overexpressed in these cancers. BI-2536, a selective PLK1 inhibitor, has shown promising anticancer activity. β-Glucan, a natural immunomodulator, has also demonstrated anticancer potential. This study aimed to evaluate the antiproliferative, apoptotic, and cell cycle effects of BI-2536 alone and in combination with β-glucan on HT-29 colon and AGS gastric cancer cell lines.
MATERIALS AND METHODS: Cell viability was assessed using the XTT assay. Apoptosis and cell cycle profiles were evaluated using flow cytometry. The combination index (CI) was calculated using the Chou-Talalay method via CompuSyn software.
RESULTS: BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-Glucan showed moderate cytotoxicity and enhanced BI-2536's effects. Synergistic antiproliferative activity was observed at lower drug concentrations, such as 2-16 nM BI-2536 combined with 31.25-250 μg/ml β-glucan (CI<1). The combination induced greater apoptosis and more pronounced G2/M arrest compared with either agent alone, demonstrating a clear synergistic effect.
CONCLUSION: BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers.
MATERIALS AND METHODS: Cell viability was assessed using the XTT assay. Apoptosis and cell cycle profiles were evaluated using flow cytometry. The combination index (CI) was calculated using the Chou-Talalay method via CompuSyn software.
RESULTS: BI-2536 significantly inhibited proliferation and induced G2/M arrest and apoptosis in both cell lines. β-Glucan showed moderate cytotoxicity and enhanced BI-2536's effects. Synergistic antiproliferative activity was observed at lower drug concentrations, such as 2-16 nM BI-2536 combined with 31.25-250 μg/ml β-glucan (CI<1). The combination induced greater apoptosis and more pronounced G2/M arrest compared with either agent alone, demonstrating a clear synergistic effect.
CONCLUSION: BI-2536 in combination with β-glucan exhibits synergistic anticancer effects in vitro, suggesting a promising strategy for treating colon and gastric cancers.